Dr. Palaniappan joined Aruvant as chief technology officer in May of 2020 bringing 25 years of research and drug development experience including extensive work in chemistry, manufacturing and controls (CMC), a critical part of drug development. He most recent served as senior vice president, head of global technical operations and head of the Andover and Burlington sites at Sarepta. He was responsible for all stages of development from research through commercial for a portfolio of over 30 compounds using three modalities, antisense RNAs, gene therapy and gene editing. Prior to Sarepta, Dr. Palaniappan worked for over a decade at Takeda where he led teams based in the United States and Japan focused on CMC development and manufacturing of novel modality products including recombinant biologics, cell-based and live microbe products. Prior to joining Takeda, he worked in various development and product manufacturing roles of increasing responsibility at Millennium Pharmaceuticals which was acquired by Takeda, Biogen and Nexstar Pharmaceuticals which was acquired by Gilead.

Dr. Palaniappan received his bachelor’s and master’s degree from Annamalai University of India. He earned his Ph.D. in Chemistry from the Indian Institute of Technology, Kanpur.